ArticleClinical Medicine Insights. Oncology2011
Trabectedin: safety and efficacy in the treatment of advanced sarcoma.
Article in Clinical Medicine Insights. Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Trabectedin may be a valuable treatment option for elderly patients with metastatic soft tissue sarcomas.Frontiers in oncology · 2024Article
- Long lasting response with trabectedin monotherapy in relapsed metastatic mesenchymal chondrosarcoma.Clinical sarcoma research · 2020Article
- Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Review
- Marine anticancer drugs and their relevant targets: a treasure from the ocean.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2019Review
- Managing sarcoma: where have we come from and where are we going?Therapeutic advances in medical oncology · 2017Review
- Molecular targeted therapy in gynaecologic malignancies: primer for radiologists.The British journal of radiology · 2016Review
- Alkaloids from marine invertebrates as important leads for anticancer drugs discovery and development.Molecules (Basel, Switzerland) · 2014Review
- Uterine leiomyosarcoma manifesting as a tricuspid valve mass.Case reports in oncology · 2013Article
- Retrospective Analysis of Trabectedin Therapy for Soft Tissue Sarcoma.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Soft tissue sarcomas (STS) are a rare group of malignancies with multiple different subtypes. Close to half of intermediate or high grade STS develop metastatic disease. Treatment of recurrent/metastatic sarcomas is quite challenging with only a few drugs showing measurable benefits. Trabectedin (ecteinascidin 743, ET-743, Yondelis) is a newly developed alkylating agent that has shown significant broad spectrum potential as a single agent second line drug alone or in combination particularly in the treatment of liposarcomas and leiomyosarcomas. Clinical benefit rates seem to favor its use especially in pretreated patients with recurrent/metastatic disease. The drug is well tolerated in general but hepatotoxicity and hematologic side effects are common. Approved in Europe, the currently ongoing Phase III trials along with the already existing clinical evidence may provide enough data for the Food and Drug Administration for an approval in the US.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.